Overview

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

Status:
Withdrawn
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Xiaojun Chen
Collaborator:
Huashan Hospital
Treatments:
Liraglutide
Megestrol
Megestrol Acetate